Literature DB >> 23745789

Radiotherapy for esophageal cancer using simultaneous integrated boost techniques: dosimetric comparison of helical TomoTherapy, Volumetric-modulated Arc Therapy (RapidArc) and dynamic intensity-modulated radiotherapy.

Yao-Ching Wang1, Shang-Wen Chen, Chun-Ru Chien, Te-Chun Hsieh, Chun-Yen Yu, Yu-Cheng Kuo, Shih-Neng Yang, Chia-Hung Kao, Ji-An Liang.   

Abstract

This study compared TomoTherapy (TM), with Volumetric-Modulated Arc Therapy (RapidArc, RA), and dynamic intensity-modulated radiotherapy (dIMRT) for locally advanced esophageal cancer (LAEC) with a simultaneous integrated boost (SIB) technique with regard to the target coverage and sparing of organs at risk (OARs). Twelve patients receiving four-dimensional computed tomography simulation were enrolled for dosimetric comparison. Gross tumor volume was contoured with the maximum intensity projection method. Using an SIB method, Planning target volume low (PTVL) and planning target volume high (PTVH) were prescribed as 54 Gy and 60 Gy, respectively, each administered in 30 fractions. We compared the results of statistical analysis for target coverage, homogeneity index (HI) and conformity index (CI) of PTVs, parameters of OARs and monitor unit (MU) were compared for analysis. The HI for PTVH varied significantly for the 3 techniques of TM, RA, and dIMRT (4.38 ± 0.86, 6.40 ± 0.86, and 6.11 ± 0.68, respectively; P , 0.001). The CI scores for PTVH also differed across TM, RA, and dIMRT (0.64 6 0.06, 0.53 6 0.06, and 0.59 ± 0.05, respectively; P < 0.001). The HI for PTVL showed a significant difference among TM, RA, and dIMRT (15.44 ± 0.88, 20.88 ± 1.03 and 18.65 ± 1.42, respectively; P < 0.001). The percentage of lung volume receiving 5 Gy (V5) and 20 Gy (V20) (for V5: TM 54.4 ± 8.0%; RA 67.5 ± 14.5%, P < 0.01; dIMRT 44.8 ± 8.2%; for V20: 13.6 6 3.3%, 12.2 ± 3.6%, 18.1 6 3.4%, P = 0.001, respectively). For RA, the lung V5 ≥ 65% was observed in 6 patients and the V10 ≥ 50 % in one patient. TM, RA and dIMRT provided comparable coverage of the target and sparing of OARs. TM demonstrated superior CI and HI for tumor coverage and lowered the specified dose parameters for lung. RA provided an advantage in terms of the lowest MU and V20 of the lung, but its higher lung V5 was of some concern about lung toxicity.

Entities:  

Mesh:

Year:  2013        PMID: 23745789     DOI: 10.7785/tcrt.2012.500348

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  5 in total

1.  Is dose escalation achievable for esophageal carcinoma?

Authors:  Laure Vieillevigne; Marie Vidal; Françoise Izar; Michel Rives
Journal:  Rep Pract Oncol Radiother       Date:  2015-01-05

2.  Volumetric modulated arc therapy versus intensity-modulated proton therapy in neoadjuvant irradiation of locally advanced oesophageal cancer.

Authors:  Eren Celik; Wolfgang Baus; Christian Baues; Wolfgang Schröder; Alessandro Clivio; Antonella Fogliata; Marta Scorsetti; Simone Marnitz; Luca Cozzi
Journal:  Radiat Oncol       Date:  2020-05-24       Impact factor: 3.481

3.  Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location.

Authors:  Lu Wang; Chengqiang Li; Xue Meng; Chengming Li; Xindong Sun; Dongping Shang; Linlin Pang; Yixiao Li; Jie Lu; Jinming Yu
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

4.  A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers.

Authors:  Antonella Fogliata; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Sarbani Laksar; Angelo Tozzi; Marta Scorsetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2015-10-31       Impact factor: 3.481

5.  Efficacy of virtual block objects in reducing the lung dose in helical tomotherapy planning for cervical oesophageal cancer: a planning study.

Authors:  Makoto Ito; Hidetoshi Shimizu; Takahiro Aoyama; Hiroyuki Tachibana; Natsuo Tomita; Chiyoko Makita; Yutaro Koide; Daiki Kato; Tsuneo Ishiguchi; Takeshi Kodaira
Journal:  Radiat Oncol       Date:  2018-04-04       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.